Cargando…
Genetic invalidation of Lp-PLA(2) as a therapeutic target: Large-scale study of five functional Lp-PLA(2)-lowering alleles
AIMS: Darapladib, a potent inhibitor of lipoprotein-associated phospholipase A(2) (Lp-PLA(2)), has not reduced risk of cardiovascular disease outcomes in recent randomized trials. We aimed to test whether Lp-PLA(2) enzyme activity is causally relevant to coronary heart disease. METHODS: In 72,657 pa...
Ejemplares similares
-
Lp-PLA2 Inhibition—The Atherosclerosis Panacea?
por: Karakas, Mahir, et al.
Publicado: (2010) -
Lp-PLA(2) Inhibitors for the Reduction of Cardiovascular Events
por: Steen, Dylan L., et al.
Publicado: (2013) -
Lp-PLA2 levels in HIV-infected patients
por: Díaz-Pollán, Beatriz, et al.
Publicado: (2014) -
The Relationship between Intracarotid Plaque Neovascularization and Lp (a) and Lp-PLA2 in Elderly Patients with Carotid Plaque Stenosis
por: Sun, Chang, et al.
Publicado: (2022) -
Association Lp-PLA2 Gene Polymorphisms with Coronary Heart Disease
por: Ma, Sha, et al.
Publicado: (2022)